Live Breaking News & Updates on Narcolepsy Type

Stay updated with breaking news from Narcolepsy type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TAK-861 Shows Promise in Phase 2b Narcolepsy Type 1 Trial

TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial. ....

Drug Administration , Breakthrough Therapy , Narcolepsy Type , Wakefulness Test , Epworth Sleepiness Scale , Weekly Cataplexy Rate , Toward Phase ,

Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - - ....

United States , Craig Hopkinson , Gretchen Murphy , Michaelj Doane , Davidt Plante , Ron Grunstein , Sandy Coombs , University Of Wisconsin , Group Study Evaluating The Safety , Research Development At Alkermes , Woolcock Institute Of Medical Research , World Sleep Congress , Circadian Research , Breaking Abstracts Containing Data From , Full Narcolepsy Type , Design Accepted , Poster Presentations , From In Depth Qualitative Patient Interviews , Narcolepsy Will Also Be Presented , Associated Professional Sleep Societies , Wakefulness Test , Karolinska Sleepiness Scale , Chief Medical Officer , Executive Vice President , Pharmacodynamic Effects , Narcolepsy Type ,

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says - Alkermes (NASDAQ:ALKS)

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680. ....

Wakefulness Test , Narcolepsy Type , Idiopathic Hypersomnia ,

Psychiatry in the News: February 2024

Here are some updates from the world of psychiatry throughout the month of February. ....

Sarah Sheikh Msc , National Institute On Drug , Mental Health Services Administration , Drug Administration , Us Department Of Health , Human Services , Psychiatric Times , Grants Priority Review , Assisted Therapy , New Drug Application , Prescription Drug User Fee Act , Oral Orexin Receptor , Narcolepsy Type , Sarah Sheikh , Neuroscience Therapeutic Area Unit , Grant Funding , Substance Use Disorder Treatment , Substance Abuse , National Institute , Drug Use ,

Essen Bakery offers up sweet treats to aid with Rare Disease Day – Metro US

Essen Bakery owner Tova du Plessis recently took to social media to document her struggle and recent diagnosis of Narcolepsy Type 1. She has been struggling with the rare disease for 14 months, and according to her, that time has been “debilitating”, making it difficult to run the bakery and oversee the brand’s expansion to […] ....

United States , Fishtown Kensington , Lisa Ludwinski , James Beard , Bon Appetit , Essen Bakery , Narcolepsy Type , Rare Disease Day , Sister Pie , James Beard Award , Bon Appetit , Wake Up Narcolepsy ,